[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$NVCT NXP900 #ANE2025 abstract title 10/23: A099 NXP900 a novel YES1/SRC kinase inhibitor currently in clinical development potently inhibits tumor growth in FAT1 mutated xenograft models. Asier Unciti-Broceta. University of Edinburgh Edinburgh UK. The new FAT1-mutant PDX work extends the preclinical models into human-derived systemsreinforcing the translational bridge that defines NXP900s biomarker-guided clinical strategy. ➡ As the first human PDX study of NXP900 it builds on prior TNBC in-vivo data and substantiates the logic behind FAT1 loss as a key biomarker for patient enrichment in"
X Link @JD4for4 2025-10-13T18:11Z 8285 followers, 1774 engagements
"Live Day Trading a XXX% Short Squeeze $ISPO $ANGH $NVCT"
YouTube Link @daytradewarrior 2022-02-17T21:35Z 1.9M followers, 58.1K engagements